these modifications could be adaptive changes that might alter susceptibility to artemisinins.
Cojean et al. found the S769N mutation in an isolate from Africa that was susceptible to dihydroartemisinin (1), while Noedl et al. did not find this mutation in Cambodian samples that were less susceptible to artesunate (11) . Consequently, we speculated on whether the correlation between the S769N mutation and the increased artemether 50% inhibitory concentration found in six isolates from French Guyana (7) should be regarded as a local case. Like other investigators, we did not detect any polymorphism in codon 263, described as the key amino acid for the interaction between PfATP6 and artemisinins (13) . Mutations observed in our sequences and in those of previous studies (2, 6, 9) could be implicated indirectly in this interaction, in the case of association with artemisinin susceptibility. Considering the development of artemisinin combined therapies and the possible implication of PfATP6 in artemisinin resistance, the molecular variability of this gene should be carefully monitored. T266C  I89T  13  12  T1380C  N460N  1  A1388G  N463S  3  ⌬463-464  1  A1395G  N465S  2  T2049A  N683K  5  2  T2694A  I898I  91  5  C3093T C1031C 3
a The total number of samples analyzed was 98.
